WO2000005223A3 - Composes chimiques - Google Patents

Composes chimiques Download PDF

Info

Publication number
WO2000005223A3
WO2000005223A3 PCT/GB1999/002330 GB9902330W WO0005223A3 WO 2000005223 A3 WO2000005223 A3 WO 2000005223A3 GB 9902330 W GB9902330 W GB 9902330W WO 0005223 A3 WO0005223 A3 WO 0005223A3
Authority
WO
WIPO (PCT)
Prior art keywords
group
linked
formation
amide bond
ch2ch2s
Prior art date
Application number
PCT/GB1999/002330
Other languages
English (en)
Other versions
WO2000005223A2 (fr
Inventor
David Robert Brittain
Craig Johnstone
Gareth Morse Davies
Michael Stewart Large
Original Assignee
Astrazeneca Ab
David Robert Brittain
Craig Johnstone
Gareth Morse Davies
Michael Stewart Large
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815970.0A external-priority patent/GB9815970D0/en
Priority claimed from GBGB9815972.6A external-priority patent/GB9815972D0/en
Priority claimed from GBGB9914441.2A external-priority patent/GB9914441D0/en
Application filed by Astrazeneca Ab, David Robert Brittain, Craig Johnstone, Gareth Morse Davies, Michael Stewart Large filed Critical Astrazeneca Ab
Priority to EP99934885A priority Critical patent/EP1133484A2/fr
Priority to AU50521/99A priority patent/AU5052199A/en
Priority to JP2000561179A priority patent/JP2002521375A/ja
Publication of WO2000005223A2 publication Critical patent/WO2000005223A2/fr
Publication of WO2000005223A3 publication Critical patent/WO2000005223A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B41/00—After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone
    • C04B41/009—After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone characterised by the material treated
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B41/00—After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone
    • C04B41/45—Coating or impregnating, e.g. injection in masonry, partial coating of green or fired ceramics, organic coating compositions for adhering together two concrete elements
    • C04B41/4572—Partial coating or impregnation of the surface of the substrate
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B41/00—After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone
    • C04B41/80—After-treatment of mortars, concrete, artificial stone or ceramics; Treatment of natural stone of only ceramics
    • C04B41/81—Coating or impregnation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Ceramic Engineering (AREA)
  • Immunology (AREA)
  • Materials Engineering (AREA)
  • Diabetes (AREA)
  • Structural Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'invention concerne un composé de la formule (I) dans laquelle: A représente un hétéroaryle bicyclique éventuellement substitué par un ou plusieurs substituants; B représente un aryle ou un hétéroaryle mono ou bicyclique, chacun pouvant être éventuellement substitué par un ou plusieurs substituants; Z représente -(CRaRb)aCO, -NH, -CO ou le groupe -X-(CH2)bCONH(CH2)cNH dans lequel X désigne de l'oxygène, du soufre, un amino, un alkylamino ou une liaison directe, Ra et Rb représentent indépendamment un hydrogène ou un alkyle en C¿1-6?, a désigne un entier de 1 à 4, b désigne 1 ou 2 et c est compris entre 2 et 5 et; W représente -HCH(R?w¿)CO- ou OC(Rw)CHNH, Rw représentant -H¿2?CH(CH3)2 -CH2CH2S(CH3) ou CH2CH2S(O2)(CH3); q désigne 0 ou 1 et lorsque q désigne 0, Z est lié au groupe Y par formation d'une liaison amide entre Z et Y, et lorsque q désigne 1, Z est lié au groupe W par formation d'une liaison amide entre Z et W et W est lié au groupe Y par formation d'une liaison amide entre W et Y; Y représente un fragment dérivé de l'extrémité C-terminale d'un composé qui inhibe l'interaction entre l'intégrine αIIbβ3 et son ligand fibrinogène; R?1¿ représente un hydrogène, un alkyle en C¿1-3?, un alcanoyle en C1-3 ou un alcoxycarbonyle en C1-3; ou alors, l'invention concerne un sel de ce composé acceptable du point de vue pharmaceutique ou un dérivé de ce composé pouvant être hydrolysé in vivo.
PCT/GB1999/002330 1998-07-23 1999-07-20 Composes chimiques WO2000005223A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99934885A EP1133484A2 (fr) 1998-07-23 1999-07-20 Composes chimiques
AU50521/99A AU5052199A (en) 1998-07-23 1999-07-20 Chemical compounds
JP2000561179A JP2002521375A (ja) 1998-07-23 1999-07-20 化合物

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9815970.0A GB9815970D0 (en) 1998-07-23 1998-07-23 Chemical compounds
GB9815972.6 1998-07-23
GBGB9815972.6A GB9815972D0 (en) 1998-07-23 1998-07-23 Chemical compounds
GB9815970.0 1998-07-23
GB9914441.2 1999-06-22
GBGB9914441.2A GB9914441D0 (en) 1999-06-22 1999-06-22 Chemical compounds

Publications (2)

Publication Number Publication Date
WO2000005223A2 WO2000005223A2 (fr) 2000-02-03
WO2000005223A3 true WO2000005223A3 (fr) 2001-07-12

Family

ID=27269410

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/002330 WO2000005223A2 (fr) 1998-07-23 1999-07-20 Composes chimiques

Country Status (4)

Country Link
EP (1) EP1133484A2 (fr)
JP (1) JP2002521375A (fr)
AU (1) AU5052199A (fr)
WO (1) WO2000005223A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2362862A1 (fr) 1999-02-16 2000-08-24 Aventis Pharma Limited Composes bicycliques et leur utilisation comme ligands du recepteur de l'integrine
CN1413210A (zh) 1999-12-28 2003-04-23 辉瑞产品公司 用于治疗炎症、自身免疫性疾病和呼吸系统疾病的vla－4依赖性细胞结合的非肽基抑制剂
GB0001346D0 (en) * 2000-01-21 2000-03-08 Astrazeneca Uk Ltd Chemical compounds
GB0001348D0 (en) * 2000-01-21 2000-03-08 Astrazeneca Uk Ltd Chemical compounds
GB0004686D0 (en) * 2000-02-28 2000-04-19 Aventis Pharma Ltd Chemical compounds
RU2290403C2 (ru) * 2000-12-28 2006-12-27 Дайити Фармасьютикал Ко., Лтд. Ингибиторы vla-4
ZA200304059B (en) * 2000-12-28 2004-07-06 Daiichi Seiyaku Co VLA-4 inhibitors.
WO2003010135A1 (fr) * 2001-07-26 2003-02-06 Ajinomoto Co., Inc. Nouveaux derives de l'acide phenylpropionique
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
CA2770493A1 (fr) 2003-07-24 2005-02-03 Daiichi Pharmaceutical Co., Ltd. Compose acide cyclohexanecarboxylique
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
DE10360745A1 (de) * 2003-12-23 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7470712B2 (en) * 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
US7524862B2 (en) 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
DE102006021878A1 (de) * 2006-05-11 2007-11-15 Sanofi-Aventis Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
WO2016089648A1 (fr) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Inhibiteurs de bach1 en combinaison avec des activateurs de nrf2 et compositions pharmaceutiques les contenant
EP3873897A1 (fr) 2018-10-30 2021-09-08 Gilead Sciences, Inc. Composés pour l'inhibition de l'intégrine alpha 4 bêta 7
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
CN112969687A (zh) 2018-10-30 2021-06-15 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
CN112969700A (zh) 2018-10-30 2021-06-15 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
WO2021030438A1 (fr) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Composés pour l'inhibition de l'intégrine alpha 4 bêta 7

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022966A1 (fr) * 1995-01-23 1996-08-01 Biogen, Inc. Inhibiteurs de l'adherence cellulaire
WO1997008145A1 (fr) * 1995-08-30 1997-03-06 G.D. Searle & Co. Derives de la meta-guanidine, de l'uree, de la thio-uree ou de l'acide aminobenzoique azacyclique utilises comme antagonistes de l'integrine
WO1997036862A1 (fr) * 1996-03-29 1997-10-09 G.D. Searle & Co. DERIVES DE PHENYLENE META-SUBSTITUES, UTILISES COMME ANTAGONISTES OU INHIBITEURS DE L'INTEGRINE ALPHAvBETA¿3?
WO1999024398A2 (fr) * 1997-11-12 1999-05-20 Astrazeneca Uk Limited Composes chimiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022966A1 (fr) * 1995-01-23 1996-08-01 Biogen, Inc. Inhibiteurs de l'adherence cellulaire
WO1997008145A1 (fr) * 1995-08-30 1997-03-06 G.D. Searle & Co. Derives de la meta-guanidine, de l'uree, de la thio-uree ou de l'acide aminobenzoique azacyclique utilises comme antagonistes de l'integrine
WO1997036862A1 (fr) * 1996-03-29 1997-10-09 G.D. Searle & Co. DERIVES DE PHENYLENE META-SUBSTITUES, UTILISES COMME ANTAGONISTES OU INHIBITEURS DE L'INTEGRINE ALPHAvBETA¿3?
WO1999024398A2 (fr) * 1997-11-12 1999-05-20 Astrazeneca Uk Limited Composes chimiques

Also Published As

Publication number Publication date
EP1133484A2 (fr) 2001-09-19
AU5052199A (en) 2000-02-14
JP2002521375A (ja) 2002-07-16
WO2000005223A2 (fr) 2000-02-03

Similar Documents

Publication Publication Date Title
WO2000005223A3 (fr) Composes chimiques
MXPA04006322A (es) Derivados de 6-fluorobiciclo[3.1.0]hexano.
ES2196396T3 (es) Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa.
EA200100755A1 (ru) 4-оксо-1,4-дигидро-3-хинолинкарбоксамиды как антивирусные агенты
MX9709951A (es) Derivados de benzamida y su uso como antagonistas de vasopresina.
WO2003039451A3 (fr) Derive de thiazole et utilisation pharmaceutique
YU69902A (sh) Novi derivati piperazina
YU48390B (sh) Novi derivati 2-anilinopirimidina, postupak za njihovo dobijanje i sredstva za uništavanje štetočina, koja sadrže ove derivate
RS52326B (en) Phenyl-piperazine Derivatives As Serotonin Resorption Inhibitors
SI1585739T1 (sl) Substituirani arilciklopropilacetamidi kot aktivatorji glukokinaze
DE60140456D1 (de) Aza heterocyclische derivate und ihre therapeutische verwendung
CA2429642A1 (fr) Activateurs de glucokinase heteroaromatiques fusionnes
ES8701173A1 (es) Procedimiento para la fabricacion de derivados de pirazol tienil condensados
WO2002044153A8 (fr) Derives de 4-aryle pyridine
NZ514662A (en) Amine derivatives
CA2179640A1 (fr) Antifongiques de type azole solubles dans l'eau
AU2267495A (en) Benzamide derivatives as vasopressin antagonists
CO4410329A1 (es) Nuevos pirrolocarbazoles
AUPP150098A0 (en) Benzamide derivatives
ES2137512T3 (es) Derivados de amidina biciclicos como inhibidores de la sintetasa de oxido nitrico.
MY138051A (en) Compounds and processes
WO2003031414A1 (fr) Nouveau compose heterocyclique et agent anti-inflammatoire
WO2000005224A3 (fr) Composés chimiques
IE43651L (en) Benzisoquinolin-piperidine derivatives
EP1661898A4 (fr) Compose de piperazine bicyclique et utilisation de ce dernier

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1999934885

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 561179

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09744329

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 1999934885

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999934885

Country of ref document: EP